ÄÁÅÙÃ÷»ó¼¼º¸±â

Äڷγª-19 ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ÀÌÇØ : ½Ç³» ¿Í ½Ç¿Ü È°µ¿ ¿¬±¸
Äڷγª-19 ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ÀÌÇØ : ½Ç³» ¿Í ½Ç¿Ü È°µ¿ ¿¬±¸
  • ÀúÀÚJie Yu, Peiwei Chai, Shengfang Ge, Xianqun Fan Àú
  • ÃâÆÇ»ç¾ÆÁø
  • ÃâÆÇÀÏ2020-07-12
  • µî·ÏÀÏ2020-12-21
º¸À¯ 1, ´ëÃâ 0, ¿¹¾à 0, ´©Àû´ëÃâ 8, ´©Àû¿¹¾à 0

Ã¥¼Ò°³

In late December 2019, an unprecedented outbreak of coronavirus disease 2019
(COVID-19) caused by SARS coronavirus 2 (SARS-CoV-2) (previously named
2019-nCoV) in Wuhan became the most challenging health emergency. Since its
rapid spread in China andmany other countries, theWorld HealthOrganization
(WHO) declared COVID-19 a public health emergency of international concern
(PHEIC) on 30th January 2020 and a pandemic on 11th March 2020. Thousands of
people have died, and there are currently no vaccines or specific antiviral drugs
for COVID-19. Therefore, it is critical to have a comprehensive understanding of
the virus. In this review, we highlight the etiology, epidemiology, pathogenesis and
pathology, clinical characteristics, diagnosis, clinical management, prognosis,
infection control and prevention of COVID-19 based on recent studies.
µî·Ï»óÇ¥

¸ñÂ÷

Á¦ 1Æí Äڷγª¹ÙÀÌ·¯½º Á¤ÀÇ
1. Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(Covid-19) Á¤º¸ 7
2. Äڷγª¹ÙÀÌ·¯½º ºÐ·ù ¹× Æ¯¼º 9
3. Äڷγª¹ÙÀÌ·¯½º ÀüÀÚÇö¹Ì°æ ÇüÅ 11
4. Äڷγª¹ÙÀÌ·¯½º ±¸Á¶ (Covid-19 Organization) 13
5. Äڷγª19: È¯°æ¿¡ Áö¼ÓÀûÀΠ¿µÇâÀ» ¹ÌÄ¥±î? 19
6. Ä¡·á¹ý(Therapeutical Method) 22

Á¦ 2Æí ¿¬±¸³í¹®
Recent Understandings Toward Coronavirus Disease 2019
(COVID-19): From Bench to Bedside

1. Introduction 23
2. ETIOLOGY 24
3. EPIDEMIOLOGY 25
4. PATHOGENESIS AND PATHOLOGY 26
5. Imaging Presentation 27
6. CLINICAL MANAGEMENT 28
7. Neonates With COVID-19 29
8. DISCUSSION 30
9. References 31

ÇÑÁÙ ¼­Æò